Group 1 - The core viewpoint highlights the rapid enhancement of the "first industry" capability in Suzhou Industrial Park, driven by precise policy support and deep capital empowerment, particularly in the biopharmaceutical sector [1] - In 2023, six innovative Class I drugs were approved for market release in the park, accounting for approximately 20% of the national total, showcasing the growing "innovation source" effect in biomedicine [2] - The park has attracted over 2,000 related enterprises since 2006, with a projected output value of 165.5 billion yuan in 2024, emphasizing its strategic focus on biomedicine and health industries [1] Group 2 - The "Biopharmaceutical and Health Industry Leap Action Plan (2025-2027)" aims to cultivate five international leading enterprises, 50 leading companies in niche markets, and 100 key products with annual sales exceeding 100 million yuan by 2027 [1] - The capital market has shown active performance, with companies like Sifen Technology and Ascentage Pharma successfully listing on various stock exchanges, indicating strong market confidence in the park's biopharmaceutical capabilities [2] - The integration of artificial intelligence in research and development is reshaping the paradigm, with significant improvements in efficiency and cost reduction in drug development processes [3]
“创新策源”效应凸显 全国新增创新药五分之一在园区
Su Zhou Ri Bao·2025-08-13 00:14